Biobanking – VJRegenMed

Patient-centric innovations in the supply chain

Simon Ng — Mon, 28 Feb 2022 17:56:21 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, gives an overview of patient-centric approaches in improving the supply chain for advanced therapies, which usually cannot be administered at home. Long term storage of therapies will benefit patients who will need further doses and biobanking enables healthy cells to be retained if they are required for manufacturing new products. A decentralized approach is additionally required, especially for patients receiving chimeric antigen receptor (CAR) T-cell therapy, as they will benefit from long-term care from their own homes. This interview took place at Advanced Therapies Week 2022.

The logistics of manufacturing allogeneic therapies on a large scale

Simon Ng — Thu, 17 Feb 2022 12:04:59 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, discusses changes that are needed in the supply chain to adapt to an increasing demand in allogeneic therapies. Pivoting to a one-to-many supply chain is crucial to successfully manufacture allogeneic therapies on a larger scale, as well as focusing on local suppliers and storage, especially in the light of the COVID-19 pandemic. She additionally highlights the need to increase biobanking capabilities as the industry shifts to allogeneic therapies. This interview took place at Advanced Therapies Week 2022.

Umbilical cord blood infusions in children with cerebral palsy

admin_vjr_user — Tue, 20 Jul 2021 07:56:43 +0000

Joanne Kurtzberg, MD, Duke University, Durham, NC, describes ongoing research evaluating the potential of umbilical cord blood infusion in pediatric patients with cerebral palsy. A randomized Phase II trial (NCT01147653) indicated that the infusion of autologous umbilical cord blood (UCB) at a dose of 25 million cells per kilogram or higher resulted in improvement in gross motor function. In addition, the open-label Phase II ACCeNT-CP trial (NCT03473301), which compared a single high dose of allogeneic UCB with repeated infusions of cord tissue mesenchymal stromal cells (MSCs), demonstrated that UCB infusion improved motor function and has prompted the initiation of a Phase III trial. This interview took place at the 2021 World Stem Cell Summit (WSCS).